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Rationale: Nuclear receptors play a critical role in the regulation of
inflammation, thus representing attractive targets for the treat-
ment of asthma.
Objective: In this study, we assess the potential regulatory function
of retinoid-related orphan receptor  (ROR) in the adaptive im-
mune response using ovalbumin (OVA)-induced airway inflamma-
tion as a model.
Methods: Allergen-induced inflammation was compared between
wild-type (WT) and staggerer (RORsg/sg) mice, a natural mutant
strain that is deficient in ROR expression.
Measurements and Main Results: Despite robust increases in OVA-
specific IgE, RORsg/sg mice developed significantly less pulmonary
inflammation, mucous cell hyperplasia, and eosinophilia compared
with similarly treated WT animals. Induction of Th2 cytokines, in-
cluding interleukin (IL)-4, IL-5, and IL-13, was also significantly less
in RORsg/sg mice. Microarray analysis using lung RNA showed in-
creased expression of many genes, previously implicated in inflam-
mation, in OVA-treated WT mice. These include mucin Muc5b, the
chloride channel calcium-activated 3 (Clca3), macrophage inflam-
matory protein (MIP) 1 and 1, eotaxin-2, serum amyloid A3
(Saa3), and insulin-like growth factor 1 (Igf1). These genes were
induced to a greater extent in OVA-treated WT mice relative to
RORsg/sg mice.
Conclusions: Our study demonstrates that mice deficient in ROR
exhibit an attenuated allergic inflammatory response, indicating
that ROR plays a critical role in the development of Th2-driven
allergic lung inflammation in mice, and suggests that this nuclear
receptor should be further evaluated as a potential asthma target.
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Asthma is a common, chronic inflammatory disease of the lung.
Asthmatic episodes are triggered by a variety of environmental
agents, and an increasing number of genetic factors are being
identified that are important in the susceptibility to allergic air-
way disease (1, 2). Asthma is a complex genetic disorder charac-
terized by local and systemic allergic inflammation that leads to
airway hyperresponsiveness (AHR), mucosal edema, and mucus
hypersecretion by goblet cells, major causes of airway obstruc-
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Nuclear receptors with antiinflammatory effects are promis-
ing pharmacological targets, and may offer novel therapeu-
tic strategies for asthma.
What This Study Adds to the Field
Retinoid-related orphan receptor  (ROR) plays a critical
role in the development of allergic lung inflammation, sug-
gesting that this receptor should be further evaluated as a
potential asthma target.
tion (1, 3, 4). Allergen-induced inflammation involves interac-
tions and cooperation of many cell types. Activation of CD4
lymphocytes plays a critical role in the early phase of this in-
flammatory cascade by releasing interleukin (IL)-4, IL-5, and
IL-13. These Th2-type cytokines trigger a host of additional
responses, including infiltration and activation of eosinophils,
release of additional chemokines/cytokines, and induction of
serum immunoglobulin E (IgE) production (5–7). Airway re-
modeling, defined as structural changes of the airways, is a gen-
eral feature of asthma and includes increased collagen deposi-
tion, increased thickness of basement membrane, and airway
smooth muscle cell hypertrophy (1, 8).
Nuclear receptors constitute a superfamily of ligand-dependent
transcription factors that include receptors for steroid hormones,
retinoic acid, thyroid hormone, and orphan receptors for which
ligands have not yet been identified (9). Several nuclear recep-
tors, including the glucocorticoid receptor (GR), the peroxisome
proliferator-activated receptors (PPARs), and vitamin D recep-
tor (VDR), have been reported to negatively regulate airway
inflammation (10–14). VDR-deficient mice fail to develop exper-
imental allergic asthma, thereby implicating VDR in the regula-
tion of Th2-driven lung inflammation (14). A link between VDR
and lung inflammation is further indicated by studies showing
an association between VDR genetic variants and susceptibility
to asthma (15, 16). Glucocorticoids, which mediate their action
by binding GR, are effective antiinflammatory agents and the
first-line treatment of asthma (17, 18). However, long-term treat-
ment, particularly with oral steroids, has a number of adverse
effects, including stunted growth in children and osteoporosis
and high blood pressure in adults. Moreover, a subset of patients
have disease that is refractory to glucocorticoids, further high-
lighting a need for additional therapies (18–20). Other nuclear
receptors with antiinflammatory effects are promising pharmaco-
logic targets, and may offer novel therapeutic strategies for asthma.
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The retinoid-related orphan receptor (ROR) subfamily of
nuclear receptors consists of ROR, ROR, and ROR (named
NR1F1 to 3 and RORA to C by the Nuclear Receptor No-
menclature Committee and the Human Gene Nomenclature
Committee, respectively) (21–23). Several studies have provided
evidence for a role of ROR in the regulation of a number of
immune functions (22, 24–29). In vitro stimulation of peritoneal
macrophages from RORsg/sg mice, a natural mutant strain with
a disruption in ROR expression due to a deletion in the ROR
gene, by LPS results in increased induction of IL-1, IL-1, and
tumor necrosis factor  (TNF-) (27). This enhanced production
of cytokines may account for the greater sensitivity of RORsg/sg
mice to LPS-induced lung inflammation (30).
The aim of this study was to assess the role of ROR in
adaptive immunity. To investigate this, we used ovalbumin
(OVA)-induced airway inflammation in wild-type (WT) and
RORsg/sg mice as a model of allergic airway disease. We examined
whether deficiency in ROR alters the induction of several well-
established events in this model, including the degree of airway
inflammation, mucous cell hyperplasia, AHR, and the release
of several proinflammatory cytokines/chemokines. In addition,
microarray analysis was performed to identify additional changes
in gene expression associated with OVA-induced airway in-
flammation and to determine whether these changes would be
affected by the lack of ROR expression. Our results demon-
strate that RORsg/sg mice exhibit a greatly reduced Th2-driven,
airway inflammatory response, suggesting that ROR plays a
regulatory role in the development of adaptive immune re-
sponses and might be a potential target for asthma therapy.
METHODS
Experimental Animals
Heterozygous C57/BL6 staggerer mice (ROR/sg) were purchased from
Jackson Laboratories (Bar Harbor, ME) and bred at the National
Institute of Environmental Health Sciences (NIEHS). Mice were geno-
typed by polymerase chain reaction (PCR) of tail DNA according to
the instructions provided by Jackson Laboratories. RORsg/sg mice were
also easily identified by their staggerer phenotype (29, 31). WT lit-
termates were used as control mice. Because RORsg/sg mice weigh 20%
less than WT mice, cell numbers and cytokine levels were adjusted
for the differences in weight of the mice. All animal studies followed
guidelines outlined by the NIH Guide for the Care and Use of Labora-
tory Animals, and protocols were approved by the Institutional Animal
Care and Use Committee at the NIEHS and the University of North
Carolina. NIH-31 feed and water were supplied ad libitum throughout
the experiments.
OVA Sensitization and Challenge
Mice were sensitized by intraperitoneal injection with 20 g of chicken
egg OVA (grade V; Sigma, St. Louis, MO) emulsified in 200 l of
aluminum hydroxide adjuvant (Alhydrogel; Accurate Chemical and
Scientific Corp., Westbury, NY) for 2 consecutive days as described
(32, 33). Two weeks later, mice were challenged via the airways in a
nose-only exposure chamber with an aerosol consisting of 1% OVA
in saline for 5 consecutive days, 30 min/d. Control mice were primed
with saline. Twenty-four hours after the last exposure, airway function
was assessed and bronchoalveolar lavage (BAL) fluid and lung tissue
collected for further analysis as described (30).
RESULTS
Development of OVA-induced Airway Inflammation Is
Attenuated in RORsg/sg Mice
To examine the role of ROR in the adaptive immune response,
we compared OVA-induced airway inflammation in lungs of
WT and RORsg/sg mice. WT and RORsg/sg mice were sensitized
and challenged 2 wk later with OVA or saline as described in
Methods. Mice were subsequently examined for several charac-
teristics typically associated with OVA-induced allergic airway
inflammation. We first compared the induction of histopatho-
logic changes in the lungs of WT and RORsg/sg mice. Hematoxy-
lin and eosin–stained sections were scored using a semiquantita-
tive histopathologic scoring system by a pathologist who was
blinded to genotype and treatment. Two distinctive criteria were
used: (1) the extent of the infiltration of inflammatory cells to
the peribronchiolar/perivascular regions and (2) the degree of
infiltration into the alveolar sacs. Lungs from saline-primed WT
and RORsg/sg control mice did not exhibit any significant patho-
logic alterations or differences. In contrast, a number of histo-
pathologic differences were observed in lungs of both OVA-
challenged WT and RORsg/sg mice. The inflammatory response
in the OVA-challenged WT and RORsg/sg mice consisted of
infiltration of lymphocytes and polymorphonuclear cells (mainly
eosinophils) into the peribronchiolar and perivascular regions
of the lung. These changes were less severe in the lungs of
RORsg/sg mice compared with those of WT mice. The peribron-
chiolar/perivascular infiltrates in lungs of OVA-challenged
RORsg/sg mice ranged from minimal to mild and scored an
average of 2.1, whereas those in lungs of OVA-challenged WT
mice were moderate and scored an average of 3.3 (Figure 1;
p  0.001). In addition to the peribronchiolar/perivascular
changes, an accumulation of lymphocytes, neutrophils, eosino-
phils, and macrophages was observed within the alveolar sacs
of lungs from both OVA-challenged WT and RORsg/sg mice.
Figure 1. Comparison of inflammatory scores between wild-type (WT)
and RORsg/sg mice. Hematoxylin and eosin–stained sections of lungs
from WT and RORsg/sg mice (n 	 25–28 in each group) that were
challenged by either saline or ovalbumin (OVA) were scored in an
unbiased manner from 0 to 4 for the extent of inflammatory cell infiltra-
tion, as described in METHODS. 0–1 indicates no or little inflammation,
and 4 represents severe inflammation. Perivascular/peribronchiolar infil-
trates (black bars) and intraalveolar infiltrates (gray bars) were scored
separately. The average histology inflammatory scores from OVA- and
saline-challenged WT and RORsg/sg mice were calculated and plotted.
Significant differences between OVA-challenged WT and RORsg/sg mice
are indicated (*p  0.001; p  0.001).
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The OVA-challenged WT mice contained a moderate inflam-
matory cell infiltration within the alveolar sacs, whereas the
extent of alveolar infiltrates was consistently less in lungs from
OVA-challenged RORsg/sg mice and ranged from minimal to
mild. The alveolar sacs in OVA-challenged WT mice also con-
tained significant numbers of multinucleated giant cells, whereas
few multinucleated giant cells were observed occasionally in
the alveolar sacs from OVA-challenged RORsg/sg mice. The
infiltration of inflammatory cells in alveolar sacs of lungs from
OVA-challenged WT mice scored an average of 3.0, whereas
those from OVA-challenged RORsg/sg mice averaged 1.2
(Figure 1; p  0.001).
Mucous Cell Hyperplasia
Allergen-induced inflammation leads to mucous cell hyperplasia
and airway obstruction. We therefore examined the extent of
mucus production by periodic acid Schiff (PAS) staining of
sections of lungs of OVA-challenged WT and RORsg/sg mice.
As shown in Figures E1A and E1C of the online supplement,
very few PAS-positive cells were observed in the airways from
saline-challenged WT and RORsg/sg control mice. The number
of PAS-positive cells significantly increased after OVA exposure
(Figures E1B and E1D). However, the extent of PAS staining
was significantly lower in OVA-challenged RORsg/sg mice than
in OVA-challenged WT mice. The average PAS score for OVA-
challenged RORsg/sg mice was 1.3 compared with 2.4 for the
airways from OVA-challenged WT mice (Figure 2).
On the basis of these histologic observations, one may con-
clude that mice deficient in ROR exhibit an attenuated OVA-
induced inflammatory response in the lung. These findings are
in agreement with the concept that ROR plays a role in the
regulation of the adaptive immune response.
Figure 2. OVA-induced mucous cell hyperplasia in airway epithelium
of WT and RORsg/sg mice. Sections of airways from saline- and OVA-
challenged WT and RORsg/sg mice (n 	 25–28 in each group) were
stained by periodic acid Schiff (PAS) and then scored in an unbiased
manner as described in METHODS. The average PAS scores were plotted.
The difference between the average PAS score of OVA-challenged WT
and RORsg/sg mice was statistically significant (*p  0.001).
Decreased Accumulation of BAL Fluid Inflammatory Cells in
OVA-challenged RORsg/sg Mice
The Th2-type response by CD4 lymphocytes is part of the
early events in the inflammatory cascade in asthma (34, 35). The
release of Th2-type cytokines, including IL-4 and IL-13, is critical
in eliciting the recruitment of other inflammatory cells. We there-
fore compared the accumulation of inflammatory cells in BAL
fluids from OVA-challenged WT and RORsg/sg mice. As shown
in Figure 3, the total number of inflammatory cells in BAL fluids
from WT and RORsg/sg control groups did not differ significantly
(p 
 0.05). OVA exposure dramatically increased the number of
inflammatory cells; however, BAL fluids from OVA-challenged
RORsg/sg mice contained a significantly lower number of cells
than those from OVA-challenged WT mice (18.7  105  2.7
vs. 5.3  105  0.4, p  0.0001). Analysis of the different types
of inflammatory cells showed that the number of macrophages
in BAL fluid was decreased in both OVA-challenged groups
(Figure 4A); however, no significant difference was observed
between WT and RORsg/sg control mice. In contrast, the BAL
fluids from OVA-challenged RORsg/sg mice contained a signifi-
cantly lower number of eosinophils and neutrophils than those
from OVA-challenged WT mice (Figures 4B and 4C; p  0.0001).
In addition, the total number of lymphocytes in BAL fluid from
OVA-challenged RORsg/sg mice was much lower than that from
OVA-challenged WT mice (Figure 5A; p  0.0001). To examine
the effect of ROR deficiency on the different subsets of lympho-
cytes recruited to the airway, flow cytometric analysis was per-
formed on cells isolated from BAL fluid from OVA-challenged
WT and RORsg/sg mice, and the saline-challenged control
groups. This analysis showed that the numbers of CD3,
CD3CD4, CD3CD8, and B220 cells were significantly
Figure 3. Decreased OVA-induced inflammation in RORsg/sg mice corre-
lates with reduced accumulation of inflammatory cells in bronchoal-
veolar lavage fluid (BALF). Mice (n 	 25–28 in each group) were sensi-
tized with OVA and 2 wk later challenged with either OVA or saline.
Twenty-four hours after the final saline or OVA challenge, mice were
killed, BALF collected, and the total number of inflammatory cells deter-
mined in a Coulter counter. A significant difference in the total number
of inflammatory cells was observed between OVA-challenged WT and
RORsg/sg mice (*p  0.0001).
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Figure 4. Reduced infiltration of eosinophils and neutrophils in BALF
from OVA-challenged RORsg/sg mice compared with WT mice. After
saline and OVA exposure, BALF (n 	 25–28 in each group) was collected,
and the number of macrophages, neutrophils, and eosinophils were
determined as described in METHODS. (A ) The number of macrophages
decreased in both OVA-challenged WT and RORsg/sg mice (^p  0.001;
p  0.001). Significant differences (*p  0.0001) were observed in the
number of (B ) neutrophils and (C ) eosinophils between OVA-challenged
WT and OVA-challenged RORsg/sg mice.
(p  0.0001) reduced in OVA-challenged RORsg/sg mice com-
pared with OVA-challenged WT mice (Figure 5B). No signifi-
cant differences were observed between the saline-challenged
(control) groups. The greatly reduced recruitment of inflamma-
tory cells observed in the lungs of OVA-challenged RORsg/sg
mice compared with those of WT mice is in agreement with our
conclusion that RORsg/sg mice are less susceptible to allergic
airway inflammation and supports a modulatory role for this
nuclear receptor in the pathogenesis of asthma.
Attenuated Release of Cytokines/Chemokines in
OVA-challenged RORsg/sg Mice
Cytokines and chemokines play a critical role in mediating many
steps in the inflammatory cascade, including migration and
activation of various inflammatory cells. Therefore, we evaluated
whether ROR influenced the production of the cytokines IL-4,
IL-5, and IL-13 and chemokines eotaxin-1 and thymus- and
activation-regulated chemokine (TARC) during OVA-induced
airway inflammation. IL-4, IL-5, and IL-13 levels were increased
Figure 5. Reduced accumulation of various lymphocyte subpopulations
in BALF from OVA-challenged RORsg/sg mice compared with WT mice.
BALF was collected and analyzed for the total number of lymphocytes
as described in METHODS. Various lymphocyte subpopulations were
examined by flow cytometry using fluorescein isothiocyanate– or
phycoerythrin-conjugated CD4, CD3, CD8, and B220 antibodies. (A )
Comparison of total number of lymphocytes. A significant difference
in the total number of lymphocytes was observed between OVA-
challenged WT and RORsg/sg mice (*p  0.0001; n 	 25–28 in each
group). (B ) Comparison of different lymphocyte subpopulations (n 	
9–16 in each group). Significant differences were observed in the CD3
(*p  0.0001), CD3CD4 (p  0.0001), CD3CD8 (#p  0.0001),
and B220 (^p  0.0001) lymphocytes between OVA-challenged WT
mice and OVA-challenged RORsg/sg mice.
in BAL fluids from both OVA-challenged RORsg/sg and WT
mice; however, the induction of these cytokines in OVA-
challenged RORsg/sg mice was significantly less than in OVA-
challenged WT mice (Figures 6A, 6D, and 6E). For example,
OVA-challenged WT mice showed a 42-fold increase in levels
of IL-13, whereas only a fourfold increase was observed in OVA-
challenged RORsg/sg mice (Figure 6A). Similarly, exposure of
WT mice to OVA challenge induced eotaxin-1 in BAL fluids
approximately 11-fold, whereas only a fivefold increase was ob-
served in OVA-challenged RORsg/sg mice (Figure 6B). TARC
was induced approximately 60- and 10-fold, respectively (Figure
6C). No change in the level of IL-2, IL-10, IL-12, or TNF- was
observed in either OVA-challenged WT or RORsg/sg mice (not
shown). These observations support the conclusion that ROR
plays an important role in the development of a Th2-driven
airway inflammatory response in the lung.
Levels of Serum IgE Are Increased in RORsg/sg Mice
Allergen-induced inflammation is associated with a significant
increase in serum IgE levels. As shown in Figure 7A, the level
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Figure 6. Reduced susceptibility of RORsg/sg
mice to OVA-induced inflammation correlates with
decreased release of several cytokines/chemokines.
BALF from saline- and OVA-challenged WT and
RORsg/sg mice (n 	 25–28 in each group) was
collected and the level of (A ) interleukin (IL)-13,
(B ) eotaxin, (C ) TARC, (D ) IL-4, and (E ) IL-5 (E)
analyzed by ELISA. Significant differences (*p 
0.0001) were observed in the level of these cyto-
kines/chemokines between OVA-challenged WT
and OVA-challenged RORsg/sg mice.
of total serum IgE was greatly elevated in unsensitized RORsg/sg
mice compared with WT mice. These data suggest a role for
ROR signaling pathway in controlling IgE levels. OVA chal-
lenge increased OVA-specific serum IgE significantly in both
WT and RORsg/sg mice (Figure 7B). This increase was even
more pronounced in RORsg/sg than in WT mice and may involve
a mechanism similar to the one responsible for the elevated
levels of total IgE. These observations indicate that the elevation
in total IgE or OVA-specific IgE in RORsg/sg mice does not
correlate with the extent of pulmonary inflammation.
Figure 7. Comparison of the level of IgE in serum
from saline- and OVA-challenged WT and
RORsg/sg mice. Sera from saline- and OVA-
challenged WT and RORsg/sg mice (n 	 12–16
in each group) were collected and assayed for
(A ) total IgE and (B ) OVA-specific IgE as de-
scribed in METHODS. A significant difference
(*p  0.0001; ∼p  0.001) was observed in total
serum IgE between saline-challenged RORsg/sg
and WT mice. A significant difference (*p 
0.0001) was observed in OVA-specific IgE be-
tween OVA-challenged WT and RORsg/sg mice
and saline-challenged mice.
AHR in RORsg/sg and WT Mice after OVA Challenge
Lung resistance (Rl) was evaluated in saline- and OVA-treated
WT and RORsg/sg mice at baseline and in response to a graded
methacholine (MCh) challenge. As shown in Figure 8, baseline
resistance (Rl) increased after OVA sensitization/challenge in
WT animals (1.3  0.07 to 1.9  0.15 cm H2O · s/ml, p 	 0.0009).
In contrast, baseline Rl between RORsg/sg saline and RORsg/sg
OVA groups was not significantly different (1.5  0.05 vs.
1.7  0.1 cm H2O · s/ml, p 	 0.12). At lower doses of Mch,
Rl was similar between OVA-exposed WT and OVA-exposed
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Figure 8. OVA-induced changes in resistance (RL) and air-
way hyperresponsiveness in RORsg/sg mice. Baseline and
methacholine (MCh)-induced changes in RL were mea-
sured in saline-exposed WT (filled squares; n 	 16), saline-
exposed RORsg/sg (open squares; n 	 16), OVA-exposed
WT (filled circles; n 	 12), and OVA-exposed RORsg/sg
(open circles; n 	 12) mice. Five measurements were taken
before MCh challenge, and measurements were taken
every 20 s after each MCh dose. Data represent mean RL
at each interval  SEM. *p  0.05 compared with RORsg/sg
group.
RORsg/sg groups. However, at higher doses of Mch, Rl was
significantly higher in the OVA-exposed WT mice. These data
suggest that airflow obstruction does not develop in OVA-
treated RORsg/sg mice, but that lack of ROR does not prevent
the development of AHR.
Changes in Gene Expression in Lungs from OVA-challenged
WT and RORsg/sg Mice
To examine the effect of ROR on the expression of additional
inflammatory biomarkers, we compared changes in gene expres-
sion induced during allergic inflammation in whole lungs of
OVA-challenged WT and RORsg/sg mice by microarray analysis
using Agilent (Palo Alto, CA) oligo-chips representing approxi-
mately 20,000 genes. We first analyzed changes in gene expres-
sion in lungs from OVA-challenged WT versus saline-challenged
WT mice. This analysis identified 1,545 changes in gene expres-
sion that were increased by 1.5-fold or more in lungs of OVA-
challenged mice and 630 genes that were reduced by 50% or
more. Table 1 provides a selective listing of several genes induced
in lungs from OVA-challenged WT mice. The complete listing
of all the changes in gene expression identified in the different
comparisons is available at http://dir.niehs.nih.gov/microarray/
jetten/home.htm. The chloride channel calcium-activated 3
(Clca3), resistin-like a (Retnla), and several chemokines, includ-
ing Ccl4 (macrophage inflammatory protein 1 [MIP-1]), Ccl3
(MIP-1), Ccl8 (monocyte chemotactic protein 2 [MCP-2]), Ccl17
(TARC), and Ccl24 (eotaxin-2), RANTES (regulated upon
activation, T-cell expressed and secreted; Ccl5), tissue inhibitor
of metalloproteinase (Timp), and insulin-like growth factor
1 (Igf1), were among the genes most highly induced in lungs
from OVA-challenged WT mice. Enhanced expression of many
of these genes has been previously implicated in inflammation (5,
7, 36). Comparison of gene expression between saline-challenged
WT and saline-challenged RORsg/sg mice showed a number of
moderate changes; however, the expression of most genes listed
in Table 1 did not differ greatly between saline-challenged WT
and RORsg/sg mice (data not shown). Comparison of RNA ex-
pression between lungs of OVA-challenged WT and OVA-
challenged RORsg/sg mice revealed a great number of differences
(for complete listing, see http://dir.niehs.nih.gov/microarray/jetten/
home.htm). Although many of the same genes were induced or
repressed in lungs of both OVA-challenged WT and OVA-
challenged RORsg/sg, the expression of many of the RNAs were
induced to a much smaller degree in OVA-challenged RORsg/sg
versus OVA-challenged WT mice (Table 1). The differential
expression of several genes, identified by microarray analysis,
was confirmed by real-time quantitative reverse transcriptase–
PCR (Figure 9). Expression of Ccl17, Ccl24, Saa3, and Igf1 was
induced to a much greater extent in OVA-challenged WT than
in OVA-challenged RORsg/sg mice. For example, Ccl17 and
Ccl24 RNAs were induced, respectively, to levels 7.6- and 8.4-
fold greater in OVA-challenged WT mice than in OVA-
challenged RORsg/sg mice. In addition to chemokines, a number
of other genes were induced to a greater extent in WT than in
RORsg/sg mice. These include the serum amyloid proteins Saa1
and Saa3, systemic inflammation markers that are positively
associated with bronchial asthma (37). MUC5b and, to a lesser
degree, MUC5ac were among the genes induced in OVA-chal-
lenged WT mice, although induction of these genes did not
significantly change in OVA-challenged RORsg/sg mice. These
results are in agreement with the observed elevated increase in
the number of mucous cells in OVA-challenged WT compared
with OVA-challenged RORsg/sg mice. The reduced induction
of Clca3, which has been implicated in the regulation of mucus
production (36, 38), may at least in part be responsible for the
observed reduction in mucous cell hyperplasia in RORsg/sg mice.
Interestingly, not all genes were affected by ROR to the same
extent, suggesting that the effect of ROR on gene expression
may be selective. Our microarray analysis shows increased ex-
pression of many inflammatory genes in OVA-treated WT mice.
These genes are induced to a greater extent in OVA-treated
WT mice relative to RORsg/sg mice. These data support our
conclusion that mice deficient in ROR exhibit an attenuated
allergic inflammatory response.
DISCUSSION
The purpose of this study was to assess the function of the
nuclear receptor ROR in the pathogenesis of allergen-induced
airway inflammation. To study the potential role of this receptor,
we used RORsg/sg mice as a model to examine the effect of
ROR deficiency on several well-known events associated with
allergen-induced airway inflammation. Histologic observations
show that OVA challenge induces infiltration of inflammatory
cells, including eosinophils, neutrophils, and lymphocytes, into
peribronchiolar and perivascular regions and within the alveolar
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TABLE 1. SELECTIVE LIST OF GENES INDUCED IN LUNGS FROM OVALBUMIN-CHALLENGED
WILD-TYPE VERSUS SALINE-CHALLENGED (CONTROL) WILD-TYPE OR
OVALBUMIN-CHALLENGED RORsg/sg MICE
Level of mRNA (Ratio)
OVA-WT/ OVA-WT/
Genbank Entry Description Symbol Control-WT OVA-RORsg/sg
NM_011315 Serum amyloid A 3 Saa3 15 10
NM_019577 Small inducible cytokine A24 (eotaxin-2) Ccl24 28 8.4
NM_011332 Chemokine (C-C motif) ligand 17 (TARC) Ccl17 20 7.6
NM_013652 Chemokine (C-C motif) ligand 4 (MIP-1) Ccl4 5.0 5.0
NM_008491 Lipocalin 2 Lcn2 10 4.6
NM_011337 Chemokine (C-C motif) ligand 3 (MIP-1) Ccl3 8.7 4.5
NM_009117 Serum amyloid A 1 Saa1 4.3 4.2
NM_007825 Cytochrome P450, 7b1 Cyp7b1 5.3 3.3
NM_013706 CD52 antigen Cd52 5.9 3.3
NM_010512 Insulin-like growth factor 1 Igf1 7.5 3.5
NM_008605 Matrix metalloproteinase 12 Mmp12 5.0 3.5
NM_011867 Solute carrier family 26, member 4 Slc26a4 20 3.2
NM_011338 Chemokine (C-C motif) ligand 9 Ccl9 4.4 3.0
NM_007403 A disintegrin and metalloprotease domain 8 Adam8 5.0 2.9
NM_010809 Matrix metalloproteinase 3 Mmp3 3.7 2.9
NM_030712 Chemokine (C-X-C) receptor 6 Cxcr6 5.4 2.8
NM_020509 Resistin-like alpha Retnla 68 2.8
NM_011311 S100 calcium binding protein A4 S100a4 2.9 2.7
NM_011593 Tissue inhibitor of metalloproteinase Timp 9.5 2.7
NM_008380 Inhibin beta-A Inhba 4.0 2.5
NM_019467 Allograft inflammatory factor 1 Aif1 4.3 2.5
NM_013653 Chemokine (C-C motif) ligand 5 (RANTES) Ccl5 3.0 2.4
NM_010104 Endothelin 1 Edn1 3.2 2.4
AB015136 Chemokine (C-C motif) ligand 20 (MIP-3) Ccl20 2.2 2.3
NM_007802 Cathepsin K Ctsk 4.2 2.2
NM_021443 Chemokine (C-C motif) ligand 8 (MCP-2) Ccl8 3.8 2.2
NM_011331 Chemokine (C-C motif) ligand 12 Ccl12 5.5 2.1
NM_009139 Chemokine (C-C motif) ligand 6 (MRP-1) Ccl6 2.9 2.0
NM_021281 Cathepsin S Ctss 3.2 2.0
NM_008630 Metallothionein 2 Mt2 1.7 2.0
NM_007793 Cystatin B Cstb 2.7 2.0
NM_028801 Mucin 5, subtype B Muc5b 2.8 1.9
NM_008871 Proteinase inhibitor Serpine1 2.2 1.8
NM_053113 Eosinophil-associated ribonuclease A Ear11 2.1 1.8
NM_022325 Cathepsin Z Ctsz 3.5 1.7
NM_008518 Lymphotoxin B Ltb 1.8 1.7
NM_008969 Prostaglandin-endoperoxide synthase 1 Ptgs1 (Cox1) 1.7 1.6
NM_019963 Signal transducer and activator of transcription 2 Stat2 3.4 1.6
NM_011888 Small inducible cytokine A19 (MIP-3) Ccl19 4.4 1.6
NM_009896 Cytokine inducible SH2-containing protein 1 Clsh1 2.0 1.5
NM_017474 Chloride channel calcium-activated 3 Clca3 314 1.5
NM_016741 Scavenger receptor class B1 Scarb1 2.2 1.5
AK008656 Mucin 5 subtypes A and C Muc5ac 1.3 1.4
Definition of abbreviations: OVA 	 ovalbumin; WT 	 wild-type.
The ratio of the levels of respective RNA is shown. A complete listing of changes in mRNA levels can be found at http://
dir.niehs.nih.gov/microarray/jetten/home.htm.
sacs in lungs of both WT and RORsg/sg mice. However, the
degree of this infiltration was significantly less in OVA-
challenged RORsg/sg mice, showing that these mice develop a
less severe allergic inflammatory response. The reduced numbers
of eosinophils, neutrophils, and lymphocytes observed in BAL
fluid from RORsg/sg mice support this conclusion.
Allergic inflammatory responses are initiated by presentation
of the allergen by antigen-presenting cells to CD4 lymphocytes,
resulting in a Th2-type immune response (5–7, 39, 40). Induction
and release of Th2-type cytokines (e.g., IL-4, IL-5, IL-9, and
IL-13) by activated CD4 T cells play a pivotal role in the
initiation of many events that ultimately lead to pathophysiologic
abnormalities typical of asthma, namely airway obstruction and
AHR. IL-4, IL-5, and IL-13 have been implicated in the regula-
tion of several events during allergic inflammation, including
eosinophilia, induction of IgE, AHR, and excessive mucus secre-
tion. The importance of these cytokines is supported by studies
showing a link between genetic polymorphisms in the IL-4 and
IL-13 genes and the susceptibility to asthma (5, 41). Our data
show that the induction of IL-4, IL-5, and IL-13 after OVA
challenge is greatly compromised in RORsg/sg mice compared
with WT mice. Although IL-13 is synthesized by several cell types,
it is predominantly released by Th2-type CD4 T lymphocytes.
Regulation of IL-13 is complex and several inflammatory media-
tors have been implicated in the control of IL-13 (5, 42, 43).
Our data on cytokine expression appear to suggest that lack
of ROR expression affects early stages in the inflammatory
cascade.
In addition to cytokines, several chemokines were induced
to a significantly lesser extent in OVA-challenged RORsg/sg mice
than in WT mice. The levels of TARC (Ccl17) and eotaxin in
BAL fluid from RORsg/sg mice were considerably lower than
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Figure 9. Differential expression of Ccl17, Ccl24, Saa3, and
Igf1 mRNAs in lungs from saline- and OVA-challenged WT
and RORsg/sg mice. Levels of RNA were determined by real-
time quantitative reverse transcriptase–polymerase chain
reaction as described in METHODS.
those from WT mice. These findings are supported by our mi-
croarray analysis, which demonstrated that the expression of
many chemokine genes, including TARC, eotaxin-2 (Ccl24),
MCP-2 (Ccl8), and RANTES (Ccl5), was induced to a smaller
degree in lungs from OVA-challenged RORsg/sg mice than those
from WT mice (Table 1). It is likely that the reduction in various
types of inflammatory cells observed in OVA-challenged
RORsg/sg mice are related to these changes in chemokine expres-
sion. For example, eotaxins are potent eosinophil chemoattrac-
tants (44) and eotaxin-2 deficiency has been reported to cause
a reduction particularly in luminal eosinophils, whereas peri-
bronchial eosinophils were not affected (42). Therefore, the
reduction in the number of eosinophils in BAL fluid of OVA-
challenged RORsg/sg mice appears to be at least in part related
to the reduction in eotaxin-1 and eotaxin-2 expression. TARC
has been reported to be released by a number of cell types,
including macrophages, dendritic cells, natural killer cells, and
bronchial epithelial cells. It has been suggested that TARC may
provide a positive feedback mechanism that helps to sustain the
Th2-type immune response (5, 43, 45). The reduced recruitment
of CD4 lymphocytes in lungs of OVA-challenged RORsg/sg mice
might be due to the repression of TARC and might at least in
part be responsible for the attenuated Th2-driven inflammatory
response in RORsg/sg mice. IL-13 has been shown to be directly
or indirectly responsible for the induction of a vast array of
chemokines (5, 7). The reduced level of chemokine expression in
OVA-challenged RORsg/sg mice might be related to the reduced
induction of IL-13.
Induction of the Th2 immune response is accompanied by
increased serum levels of OVA-specific IgE. Interestingly, both
OVA-specific and total IgE levels were elevated in RORsg/sg
mice. Increased levels of total serum IgE have also been observed
in VDR-null mice (14). The mechanisms underlying this eleva-
tion in total IgE in both knockout mouse models are not yet
well understood and require further experimentation.
Our observation of increased Rl after OVA sensitization and
challenge in WT mice may reflect the development of airflow
obstruction in these animals, produced collectively by the in-
creased numbers of inflammatory cells in the airways, increased
mucosal edema of the airway wall secondary to products released
by these inflammatory cells, and by increased mucus released
into the airway lumen. The dramatic differences in inflammatory
cell numbers and goblet cell hyperplasia may explain the lack of
airflow obstruction at baseline in OVA-treated RORsg/sg mice.
Despite the attenuated inflammatory response observed in these
mice, AHR developed in OVA-exposed RORsg/sg mice to a
similar extent as that observed in WT animals, except at the
highest MCh dose. These findings are consistent with reports
showing a dissociation of AHR from airway eosinophilia, lung
inflammation, and IgE levels (46, 47). At higher doses, MCh
responsiveness tended to be lower in RORsg/sg mice than WT
animals. It has been shown previously that IL-13 is important
to the development of AHR, and the lower levels of IL-13
observed in OVA-treated RORsg/sg mice may, in part, explain
this attenuation (48, 49).
To assess differences in gene expression in lungs from WT and
RORsg/sg mice after OVA challenge, we performed microarray
analysis using RNA from whole lung. Gene expression analysis
using whole lung versus cultured cells has both advantages and
disadvantages. Clearly, regulation of specific genes can be more
easily studied in cultured cells. However, allergic inflammation
is a complex disease in which migration of immune cells, cell–cell
interactions, and tissue remodeling play an important role. These
complexities are not reflected in isolated culture systems. Fur-
thermore, the induction of many genes, such as those encoding
cytokines/chemokines, is tightly linked to the recruitment of
other cell types to the lung. Despite these complications, ap-
proaches like microarray analysis using whole lung may lead to
the identification of additional biomarkers to monitor inflamma-
tion in patients with inflammatory lung disease. In addition, they
may lead to the identification of additional genetic determinants
of susceptibility to asthma (50, 51). Our microarray analyses
showed that OVA-induced airway inflammation causes a large
number of changes in the pattern of gene expression in lungs
of WT mice; 588 mRNAs were up-regulated more than 2.0-fold,
whereas 630 mRNAs were decreased by more than 50% (see
http://dir.niehs.nih.gov/microarray/jetten/home.htm). Many of
these genes encode proteins that have been implicated in
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inflammation (7, 52, 53). The chemokines MIP-1 (Ccl3) and
MIP-1 (Ccl4), Retnla, Timp, metalloproteinases, endothelin 1,
the acute response proteins Saa1 and Saa3, and Igf1 were among
the genes most highly induced in lungs from OVA-challenged
WT mice. MIP-1 proteins, which act via G-protein–coupled cell
surface receptors (CCR1, CCR3, and CCR5), are expressed by
lymphocytes and monocytes/macrophages and mediate migra-
tion of neutrophils (54). The reduced expression of particularly
MIP-1 may be responsible for the diminished recruitment of
neutrophils to lungs of RORsg/sg mice. Many of the inflammatory
genes identified by microarray analysis are induced to a greater
extent in OVA-treated WT mice compared with OVA-treated
RORsg/sg mice, which therefore supports our conclusion that
mice deficient in ROR exhibit an attenuated allergic inflamma-
tory response.
It is interesting that several members of the nuclear receptor
superfamily, including GR, VDR, liver X receptor (LXR),
PPARs, and ROR regulate inflammation (10, 11, 14, 15, 18).
Recently, the retinoid X receptor (RXR) has also been shown
to play a critical role in Th2-mediated immunity (55). Although
several nuclear receptors (e.g., LXR, VDR, and PPAR) form a
heterodimer with RXR, the GR functions as a homodimer and
the ROR as a monomer, suggesting that RXR is not a common
element in the regulation of inflammation by nuclear receptors.
Several of the nuclear receptors inhibit inflammation by interfer-
ing with the activation of the nuclear factor (NF)-B signaling
pathway, which plays a critical role in Th2 cell differentiation
and is required for induction of allergic airway inflammation
(13, 56). However, nuclear receptors inhibit the NF-B signaling
pathway by distinct mechanisms. ROR has been reported to
inhibit NF-B signaling by positively regulating the expression
of IB (26). In contrast, other studies have demonstrated that
the induction of IB by LPS in lung of RORsg/sg mice was
not impaired, suggesting that ROR is not a regulator of IB
expression (30). In addition, induction of IB by LPS was
unaltered in macrophage RAW 264.7 cells expressing ROR
(30). These observations suggest that the attenuated Th2 re-
sponse in ROR-deficient mice appears to be due to an NF-
B–independent mechanism. The inhibition of allergen-induced
inflammation by PPAR is also mediated by an NF-B–
independent mechanism. The antiinflammatory response by
PPAR agonists involves an increase in IL-10 levels (11, 57).
Our results show that levels of IL-10 and of TNF- and IL-12,
two other cytokines that negatively regulate asthma (58, 59),
are not significantly altered in OVA-induced inflammation in
RORsg/sg mice, indicating that the reduced susceptibility in these
mice involves a different mechanism.
ROR is highly expressed in resting macrophages and CD4
T lymphocytes and at low levels in CD8 T lymphocytes. Al-
though the spleen and thymus in RORsg/sg mice are, respectively,
40 and 20% smaller than in WT mice (unpublished observations),
the numbers of circulating lymphocytes and neutrophils in BAL
fluid are not significantly different from those in WT mice (30).
Although RORsg/sg mice are less susceptible to allergen-induced
inflammation, these mice exhibit an increased susceptibility to
LPS-induced inflammation (30). It is well known that Th1 and
Th2 immune responses involve different cell types and cytokines
(5, 7). Because ROR can function as a repressor and activator
of transcription, a simple explanation for these different re-
sponses may be that ROR differentially regulates the expres-
sion of Th1 and Th2 cytokines.
Because nuclear receptors function as ligand-dependent tran-
scription factors, they provide excellent pharmacologic targets
to interfere in (patho)physiologic processes; therefore, they may
be very promising in yielding novel therapeutic strategies for
human disease. Glucocorticoids, which mediate their actions by
binding GR, are very effective antiinflammatory agents and are
the first-line treatment of asthma (17, 18, 20, 60–62). However,
long-term treatment with glucocorticoids is problematic due to
long-term side effects. Moreover, a subset of patients do not
respond to glucocorticoid therapy (19). Thus, additional thera-
peutic strategies are desirable. Ligands for PPARs, LXRs, and
VDRs, which have been reported to significantly influence in-
flammatory responses, may be promising candidates for addi-
tional therapeutic strategies (11, 63, 64). The attenuated OVA-
induced inflammatory response observed in mice deficient in
ROR suggests a role for this nuclear receptor in the regulation
of Th2-driven inflammation in the lung. Recent studies (65) have
identified cholesterol and cholesterol sulfate as potential agonists
of the ROR receptor. Activation of the ROR receptor by
endogenous ligands, such as cholesterol, might be implicated in
the recently reported link between obesity, hypercholesterol-
emia, and asthma (66). Synthetic, high-affinity antagonists could
prevent these recently identified endogenous ligands from acti-
vating ROR, inhibit the activation of inflammatory genes, and
have potential in the treatment of Th2-driven inflammatory dis-
eases, such as asthma and allergy.
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